Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...
Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...
Johnson & Johnson (NYSE:JNJ) today announced results from the final analysis of the Phase 3 PROTEUS study showing the investigational use of apalutamide plus hormone therapy (androgen deprivation ...
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. For patients with high-risk localized or locally advanced ...
Researchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new ...
From AI-generated biopsy reports to new imaging techniques, these are the latest developments in advanced prostate cancer research that your doctor may be keeping tabs on. Much of managing advanced ...
A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...
If you or a loved one has been diagnosed with prostate cancer, you’re not alone—and you don’t have to wait long to take the next step. Whether you’re newly diagnosed, moving from active surveillance ...
PRINCETON — Area residents will no longer have to travel far from home for advanced cancer treatment, which is now available locally. WVU Medicine Princeton Community Hospital announced Thursday the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results